• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lumos Pharma Inc (NQ: LUMO )

    3.864 +0.004 (+0.10%)
    Streaming Delayed Price Updated: 2:32 PM EDT, Oct 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lumos Pharma Inc

    < Previous 1 2 3 4 Next >
    Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma: Q4 Earnings Insights
    Via Benzinga
    Earnings Preview: Lumos Pharma
    Via Benzinga
    Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
    LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
    LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 7, 2024
    Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
    Via Benzinga
    Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
    Webinar to be Held December 6, 2023 at 1:30pm EST 
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday. 
    Via Benzinga
    Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
    Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all... 
    Via Benzinga
    Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
    Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. 
    Via InvestorPlace
    Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.